Immunology and respiratory together contribute four Phase 3 programs in Trial Watch Edition 16.
The largest study in this group is Pfizer’s 1,375 participant tilrekimig program in atopic dermatitis. GSK also advances felcorekibart through the PERSIST respiratory program, while AbbVie expands upadacitinib into pediatric alopecia areata.
Boehringer Ingelheim’s nerandomilast program adds another respiratory signal, testing whether lung focused clinical development can move earlier into defined patient groups.
The broader pattern is that mature immunology and respiratory categories are becoming more competitive. Sponsors are using larger Phase 3 designs, direct comparisons and broader platform strategies to build stronger evidence.